One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
Journals package 3months
-
http://medilib.ir
- Duration of Time : 93 Day
- :
Price : 100$- Special Price : 50$
Mechanisms of Cyst Expansion in Polycystic Kidney Disease.
doi : 10.1681/ASN.0000000643
Volume 36(4) pgs. 533-749 April 2025
Pathogenesis of Organ Damage in Fabry Disease: The AGALopathy Pathogenetic Pathway.
doi : 10.1681/ASN.0000000625
From Despair to Promise: The Dawn of Novel Treatment in IgA Nephropathy.
doi : 10.1681/ASN.0000000551
Postembryonic Maintenance of Nephron Progenitor Cells with Low Translational Activity in the Chondrichthyan Scyliorhinus canicula .
doi : 10.1681/ASN.0000000558
ATP-Gated P2X7-Ion Channel on Kidney-Resident Natural Killer T Cells and Memory T Cells in Intrarenal Inflammation.
doi : 10.1681/ASN.0000000564
Misprocessing of [alpha]-Galactosidase A, Endoplasmic Reticulum Stress, and the Unfolded Protein Response.
doi : 10.1681/ASN.0000000535
Efficacy and Safety of Ravulizumab in IgA Nephropathy: A Phase 2 Randomized Double-Blind Placebo-Controlled Trial.
doi : 10.1681/ASN.0000000534
The Selective Endothelin Receptor Antagonist SC0062 in IgA Nephropathy: A Randomized Double-Blind Placebo-Controlled Clinical Trial.
doi : 10.1681/ASN.0000000538
Long-Term Outcomes of Rituximab-Treated Adult Patients with Podocytopathies.
doi : 10.1681/ASN.0000000520
Long-Term Results from an Open-Label Extension Study of Atacicept for the Treatment of IgA Nephropathy.
doi : 10.1681/ASN.0000000541
Competing and Noncompeting Risk Models for Predicting Kidney Allograft Failure.
doi : 10.1681/ASN.0000000517
Anti-slit Antibodies against Podocin and Kirrel1 in Pediatric and Adult Podocytopathies.
doi : 10.1681/ASN.0000000642
Combination Therapy with SGLT2 Inhibitors and GLP-1 Receptor Agonists for Diabetic Kidney Disease.
doi : 10.1681/ASN.0000000620
Practical Considerations for Sharing Race-Based Genetic Research Findings.
doi : 10.1681/ASN.0000000607
Unlocking the Potential of SC0062: A New Horizon in IgA Nephropathy Treatment?.
doi : 10.1681/ASN.0000000656
Authors' Reply: Unlocking the Potential of SC0062: A New Horizon in IgA Nephropathy Treatment?.
doi : 10.1681/ASN.0000000657
Competing Risk Models Should Be Considered When Estimating Kidney Allograft Failure.
doi : 10.1681/ASN.0000000629
Authors' Reply: Competing Risk Models Should Be Considered When Estimating Kidney Allograft Failure.
doi : 10.1681/ASN.0000000630
